Gemphire Announces Initiation of Phase 2a Clinical Trial of Gemcabene in Pediatric Non-Alcoholic Fatty Liver Disease (NAFLD)
GEMPHIRE THERAPEUTICS INC COMMON (GEMP)
Last gemphire therapeutics inc common earnings: 5/9 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.gemphire.com
Company Research
Source: GlobeNewswire
Pediatric NAFLD/NASH is a large and untreated market; provides an opportunity to advance gemcabene in an underserved area with millions of affected patients Proof-of-concept clinical trial expands company’s differentiated NAFLD/NASH program across both adults and adolescents US Patent No. US 9,849,104, “Treatment of NASH with Gemcabene” issued, further enhancing intellectual property protection Company to host conference call and live webcast at 4:30 pm ET today LIVONIA, Mich., Jan. 31, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and Nonalcoholic Steatohepatitis (NASH), announced today initiation of a Phase 2a proof-of-concept (POC) clinical trial investigating gemcabene as a treatment for pediatric nonalcoholic fatty liver disease (NAFLD). NAFLD describes a continuum of disease from its mildest form of isola
Show less
Read more
Impact Snapshot
Event Time:
GEMP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GEMP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GEMP alerts
High impacting GEMPHIRE THERAPEUTICS INC COMMON news events
Weekly update
A roundup of the hottest topics